Consensus Keros Therapeutics, Inc.

Stocks

KROS

US4923271013

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-02 EDT			5-day change	1st Jan Change
11.26 ^USD	+3.49%		+2.46%	-44.70%

06-29	Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell Microcap Value Benchmark Index	CI
06-29	Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell 3000E Index	CI

Evolution of the Average Target: Keros Therapeutics, Inc.

Evolution of the Target Price: Keros Therapeutics, Inc.

Changes in Analyst Recommendations: Keros Therapeutics, Inc.

f3c38be5e768fed57255.sy1zNwhXvtxhp90j2MCorG_YbNQ0kb7Fm2JHFmd-U90.7FQFXUAPx78FlodHh_Pq2gyvC59E2Prz3S8_L1M5GJHqSwN_URP0pRDA7Q~60ab31453982ab0bdffd4ef6fad51bb7

Analysts' recommendations: Keros Therapeutics, Inc.

11-12	Oppenheimer Adjusts Keros Therapeutics Price Target to $27 From $23, Maintains Outperform Rating	MT
11-06	Wedbush Raises Price Target on Keros Therapeutics to $16 From $15, Keeps Neutral Rating	MT
25-06-10	BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32	MT
25-04-09	Truist Cuts Price Target on Keros Therapeutics to $25 From $43, Keeps Buy Rating	MT
25-01-21	Cantor Fitzgerald Downgrades Keros Therapeutics to Neutral From Overweight	MT
25-01-17	Wedbush Downgrades Keros Therapeutics to Neutral From Outperform	MT
25-01-16	Oppenheimer Cuts Price Target on Keros Therapeutics to $23 From $63, Maintains Outperform Rating	MT
24-12-23	Truist Slashes Price Target on Keros Therapeutics to $43 From $100, Keeps Buy Rating	MT
24-12-16	Guggenheim Downgrades Keros Therapeutics to Neutral From Buy	MT
24-12-12	BTIG Downgrades Keros Therapeutics to Neutral From Buy; Shares Plunge	MT
24-12-12	TD Cowen Downgrades Keros Therapeutics to Hold From Buy	MT
24-12-12	William Blair Downgrades Keros Therapeutics to Market Perform From Outperform	MT
24-12-12	Wedbush Adjusts Price Target on Keros Therapeutics to $47 From $84, Keeps Outperform Rating	MT
24-10-24	Cantor Fitzgerald Initiates Keros Therapeutics at Overweight	MT
24-10-16	Scotiabank Initiates Keros Therapeutics at Sector Outperform	MT
24-09-23	Guggenheim Initiates Keros Therapeutics at Buy With $96 Price Target	MT
24-06-25	Oppenheimer Initiates Keros Therapeutics at Outperform With $102 Price Target	MT
23-07-31	Wedbush Starts Keros Therapeutics at Outperform With $86 Price Target	MT
23-07-26	BofA Securities Initiates Keros Therapeutics With Buy Rating, $65 Price Target	MT
23-07-26	BofA Securities Starts Keros Therapeutics at Buy With $65 Price Target	MT
23-05-05	Piper Sandler Adjusts Keros Therapeutics' Price Target to $110 From $120, Keeps Overweight Rating	MT
23-02-14	Cowen Starts Keros Therapeutics at Outperform	MT
22-12-13	BTIG Adjusts Price Target on Keros Therapeutics to $105 From $95, Maintains Buy Rating	MT
22-10-18	Truist Securities Starts Keros Therapeutics at Buy With $100 Price Target	MT
22-07-26	BTIG Initiates Coverage on Keros Therapeutics With Buy Rating, $80 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	KEROS THERAPEUTICS, INC.					+93.9%
	ARGENX SE					+6.55%
	WUXI APPTEC CO., LTD.					+18%
	BIONTECH SE					+26.98%
	INSMED INCORPORATED					+76.57%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.46%
	GENMAB A/S					+23.8%
	PHARMAESSENTIA CORPORATION					-26.02%
	EXELIXIS, INC.					-10.36%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+9.75%
	Average					+24.36%
	Weighted average by Cap.					+17.89%